Multivariate Cox regression analysis of the overall survival according to RMH prognostic score and HPD adapted RECIST classes (landmark analysis). from Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Practically, patients with SD, PD and HPD lead 4.9, 16.5 and 25.9 fold increase in the death the death hazard compared to patients with CR-PR, respectively. *HPD adapted RECIST classes: complete response (CR), partial response (PR) and stable disease (SD) remained as defined by RECIST 1.1. Regarding progressive disease patients, these were allocated to PD non-HPD and to HPD. HPD patients are defined as progressive disease (PD) by RECIST 1.1 at the first evaluation and an increase {greater than or equal to} two-fold in the TGR EXPERIMENTAL compared to REFERENCE period.